CSL reports record $1.4B profit following Novartis flu vaccine purchase

CSL is now the second largest flu vaccine manufacturer in the world, thanks to its acquisition of Novartis' ($NVS) flu vaccine business. The company reported a AU$1.9 billion ($1.4 billion) full-year profit, a 6% increase over the previous year. And in spite of extra costs that expanding capacity and launching new products brings, CEO Paul Perrault expects net profit to grow around 5% per year. Story

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.